Mayo Clinic’s ImmunityBio IBRX Stock Holding History

Mayo Clinic’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,403	Closed	-$7.04K	–	6
2023 Q4	$7.04K	Buy	+1,403	New	+$4.4K	0.04%	7

Other funds holding IBRX

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mayo Clinic's IBRX Position: Q1 2024 in Review

Mayo Clinic sold out of ImmunityBio (IBRX) in Q1 2024, closing a stake of 1,403 shares — an estimated $7.04K sold.

Mayo Clinic first reported a position in IBRX in Q4 2023 and held it in 1 quarter. The position peaked at $7.04K in Q4 2023. 166 funds tracked by Wall St. Rank hold IBRX as of Q1 2024.

Mayo Clinic reported no remaining ImmunityBio position as of Q1 2024 after selling out during the quarter.
Mayo Clinic sold 1,403 ImmunityBio shares in Q1 2024, an estimated $7.04K.
Mayo Clinic first reported a position in ImmunityBio in Q4 2023 and held it in 1 quarter.
Mayo Clinic's ImmunityBio position peaked at $7.04K in Q4 2023.
166 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2024.

Based on Mayo Clinic's 13F filing for Q1 2024, filed 13 May 2024.